ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 129

Rnaseq Analysis of Human Skin in Organ Culture Identifies Collagen 22A1 As a TGF-β Early Response Gene

Tomoya Watanabe1, Logan Mlakar2, Jonathan Heywood3, Willian da Silveira4, Gary Hardiman5 and Carol A. Feghali-Bostwick6, 1Rheumatology, Medical University of South Carolina, Charleston, SC, 2Medical University of South Carolina, Charleston, SC, 3Rheumataology, Medical University of South Carolina, Chareston, SC, 4Center for Genomic Medicine, Medical University of South Carolina, Charleston, SC, 5Department of Medicine, Medical University of South Carolina, Charleston, SC, 6Department of Medicine, Medical University of South Carolina, Division of Rheumatology and Immunology, Charleston, SC

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Collagen, Fibroblasts, scleroderma and skin fibrosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a complex multi-system autoimmune disease characterized by immune dysregulation, vasculopathy, and organ fibrosis. Skin fibrosis causes high morbidity and impaired quality of life in affected individuals. In this study, we identified genes that may be involved in the development of dermal fibrosis mediated by TGF-β in human skin maintained in organ culture.

Methods: To identify new genes regulated by TGF-β in human skin, we performed high-throughput RNA sequencing using ex vivo human skin samples treated with TGF-β or a vehicle control. We identified genes whose expression is altered in human skin treated with TGF-β. Of these genes, COL22A1 showed the highest level of differential expression. The expression levels of COL22A1 and its time-dependent changes were evaluated using real-time PCR and immunoblotting (IB) in ex vivo human skin tissues and in vitro in normal human dermal fibroblasts. To investigate which TGF-β signaling cascades are involved in the induction of COL22A1 expression, normal skin fibroblasts were cultured with TGF-β in combination with specific inhibitors. Since COL22A1 was an early response gene, we sought to assess its role in the TGF-β-mediated response, thus normal skin fibroblasts were transfected with COL22A1 siRNA and then stimulated with TGF-β. Furthermore, we compared mRNA and protein levels of COL22A1 in skin fibroblasts from control donors and patients with the diffuse cutaneous form of SSc by using real-time PCR and IB.

Results: COL22A1 was most differentially expressed and its levels were significantly increased by TGF-β ex vivo and in vitro. TGF-β caused a significant increase in the expression levels of COL22A1 at earlier time points than other fibrosis associated genes. Further, TGF-β-induced COL22A1 expression was abrogated by ALK5 and MEK inhibition. Silencing of COL22A1 significantly reduced TGF-β-induced ACTA2 expression. Dermal fibroblasts from patients with diffuse cutaneous SSc showed significantly increased expression levels of COL22A1 compared with normal skin fibroblasts.

Conclusion: In conclusion, our findings suggest that the increased expression of COL22A1 is associated with the pathogenesis of fibrosis in SSc, and that the regulation of COL22A1 expression may have important implications for skin fibrosis. These results contribute novel insights into genes regulated under pro-fibrotic conditions in human skin, providing direct relevance to human dermal fibrosis.


Disclosure: T. Watanabe, None; L. Mlakar, None; J. Heywood, None; W. da Silveira, None; G. Hardiman, None; C. A. Feghali-Bostwick, GSK, Biogen, BMS, iBio Inc, 2, 7.

To cite this abstract in AMA style:

Watanabe T, Mlakar L, Heywood J, da Silveira W, Hardiman G, Feghali-Bostwick CA. Rnaseq Analysis of Human Skin in Organ Culture Identifies Collagen 22A1 As a TGF-β Early Response Gene [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/rnaseq-analysis-of-human-skin-in-organ-culture-identifies-collagen-22a1-as-a-tgf-%ce%b2-early-response-gene/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rnaseq-analysis-of-human-skin-in-organ-culture-identifies-collagen-22a1-as-a-tgf-%ce%b2-early-response-gene/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology